期刊文献+

贝曲西班的合成工艺 被引量:1

Synthetic process of betrixaban
原文传递
导出
摘要 目的:对目前贝曲西班的合成路线进行优化,以获得可用于工业生产的工艺路线。方法:以5-甲氧基-2-硝基苯甲酸和2-氨基-5-氯吡啶为起始原料制得N-(5-氯-2-吡啶基)-5-甲氧基-2-硝基苯甲酰胺,依次经过硝基还原,酰化,加成反应制得亚氨酸酯,再与二甲胺进行取代反应得到贝曲西班盐酸盐,碱解后成盐得到贝曲西班马来酸盐。结果:所得贝曲西班经HPLC检测纯度达到99.50%以上,总收率为19.63%。结论:该合成路线操作简单,收率较高,产品纯度高,适合工业化生产。 Objective: To optimize the current synthesis routes in order to develop a new synthetic route applied in betrixaban production. Methods: 5-Methoxy-2-nitro benzoic acid and 2-amino-5-chlorine pyridine were used as the starting materials to get N-(5-chloro-2-pyridinyl)-5-methoxy-2-nitrobenzamide. Imidoate was synthesized through some procedures such as nitro reduction,acylation reaction and addition reaction. The synthezed imidoate reacted with dimethylamine to get betrixaban hydrochloride,which was salified by alkaline hydrolysis to obtain the betrixaban maleate. Results: Betrixaban was synthesized with a total yield of 19. 63%,and the purity was 99. 50% determined by HPLC. Conclusion: The synthetic process is not only easy to operate with achieving high yield and purity,but also suitable for industrial production.
机构地区 河北科技大学
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第24期2902-2904,2911,共4页 Chinese Journal of New Drugs
关键词 贝曲西班 5-甲氧基-2-硝基苯甲酸 抗凝血药 合成 betrixaban 5-methoxy-2-nitro benzoic acid anticoagulants synthesis
  • 相关文献

参考文献12

二级参考文献65

  • 1Wen-Hang QI, Society of Cardiology, Chinese Medical Association. Retrospective investigation of hospitalized patientswith atrial fibrillation in China's Mainland. Int J Cardiol 2005, 105:283-287. 被引量:1
  • 2Hart RG,Pearee LA, Aguilar MI. Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med ,2007,146 : 857-867. 被引量:1
  • 3Pieeini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coil Cardio1,2009,54 : 1280-1289. 被引量:1
  • 4Bates SM, Weitz JI. The status of new anticoagulants. Br J Haemato1,2006 ,134 :3-19. 被引量:1
  • 5Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex- vivo anticoagulant activity of the direct thrombin inhibitordabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost, 2007,98 : 155-162. 被引量:1
  • 6Stangier J,Rathgen K, St? hie H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a neworal direct thrombin inhibitor,in healthy male subjects. Br J Clin Pharmacol, 2007,64:292-303. 被引量:1
  • 7Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet, 2008,47:285-295. 被引量:1
  • 8Sanford M, Plosker GL. Dabigatran etexilate. Drugs, 2008,68 : 1699-1709. 被引量:1
  • 9Eriksson BI,Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared withenoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO Ⅱ randomized trial. JThromb Haemost, 2005 ;3:103-111. 被引量:1
  • 10Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the Re-modelrandomized trial. J Thromb Haemost, 2007,5:2178-2185. 被引量:1

共引文献31

同被引文献6

  • 1A G Turpie, K A Bauer, B L Davidson et al. Thromb Haemost, 2009, 101 ( 1 ) : 68 -76. 被引量:1
  • 2M Palladino, G Merli, L Thomson. Expert Opin. lnvestig. Drugs, 2013, 22(11) : 1465 - 1472. 被引量:1
  • 3B Y Zhu, P Zhang. WO, 2001064643. 2000-02-29. 被引量:1
  • 4P Anjali, E P T Leitao, R Jose et al. WO, 2011084519. 2009-12-17. 被引量:1
  • 5G Craig, J P Kanter, L Graeme. US, 2007112039. 2007-05- 17. 被引量:1
  • 6J P Kanter, K Sujino, S S Zuberi et al. WO, 2011084519. 2006-11-02. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部